Company Ticker News November 3, 2021Should You Buy Regeneron Pharmaceuticals (REGN) Ahead of Earnings? 0 0 Share
Press Release November 1, 2021Will Eylea, Dupixent, REGEN COV Aid Regeneron (REGN) Q3 Earnings? 0 0 Share
Company Ticker News October 25, 2021Regeneron Looks Oversold, Ready To Jump Up On Catalysts 0 0 Share
Press Release October 25, 2021Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease 0 0 Share
Press Release October 25, 2021Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease 0 0 Share
Press Release October 22, 2021Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease 0 0 Share
Press Release October 22, 2021Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease 0 0 Share
